Hansa Biopharma AB
Research Hansa Biopharma AB (HNSA) on Bullrun: market cap SEK 3.50B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerHNSA
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Market capSEK 3.50B
- Financial periodFY2024
- RevenueSEK 171.32M
- Revenue growth27.8%
- Net income-SEK 807.24M
- Free cash flow-SEK 675.00M
- Gross margin51.2%
Valuation Snapshot
latest market cap is SEK 3.50B.
About Hansa Biopharma AB
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test.
Frequently asked questions
What is Hansa Biopharma AB's market cap?
Hansa Biopharma AB's market capitalization is SEK 3.50B.
What does Hansa Biopharma AB do?
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe.